153 related articles for article (PubMed ID: 16258446)
1. Strategies for the treatment of imatinib-resistant chronic myeloid leukemia.
Hui CH; Hughes TP
Clin Adv Hematol Oncol; 2003 Sep; 1(9):538-45, 559. PubMed ID: 16258446
[TBL] [Abstract][Full Text] [Related]
2. Strategies for overcoming imatinib mesylate resistance in chronic myelogenous leukemia.
Singh T; Casson C
Am J Ther; 2007; 14(5):484-7. PubMed ID: 17890939
[TBL] [Abstract][Full Text] [Related]
3. Synergistic interactions between 12-0-tetradecanoylphorbol-13-acetate (TPA) and imatinib in patients with chronic myeloid leukemia in blastic phase that is resistant to standard-dose imatinib.
Fang B; Song Y; Han Z; Wei X; Lin Q; Zhu X; Yang R; Sun J; Tian G; Liu X; Cao G; Shi Y; Nie N; Li D; Zhao RC
Leuk Res; 2007 Oct; 31(10):1441-4. PubMed ID: 17383001
[TBL] [Abstract][Full Text] [Related]
4. Specific targeted therapy of chronic myelogenous leukemia with imatinib.
Deininger MW; Druker BJ
Pharmacol Rev; 2003 Sep; 55(3):401-23. PubMed ID: 12869662
[TBL] [Abstract][Full Text] [Related]
5. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.
Chen R; Gandhi V; Plunkett W
Cancer Res; 2006 Nov; 66(22):10959-66. PubMed ID: 17108134
[TBL] [Abstract][Full Text] [Related]
6. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Reed SD; Anstrom KJ; Ludmer JA; Glendenning GA; Schulman KA
Cancer; 2004 Dec; 101(11):2574-83. PubMed ID: 15493042
[TBL] [Abstract][Full Text] [Related]
8. Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia.
White D; Saunders V; Grigg A; Arthur C; Filshie R; Leahy MF; Lynch K; To LB; Hughes T
J Clin Oncol; 2007 Oct; 25(28):4445-51. PubMed ID: 17906206
[TBL] [Abstract][Full Text] [Related]
9. Imatinib alone and in combination for chronic myeloid leukemia.
Druker BJ
Semin Hematol; 2003 Jan; 40(1):50-8. PubMed ID: 12563611
[TBL] [Abstract][Full Text] [Related]
10. Investigational strategies in chronic myelogenous leukemia.
Cortes JE; O'Brien SM; Giles F; Alvarez RH; Talpaz M; Kantarjian HM
Hematol Oncol Clin North Am; 2004 Jun; 18(3):619-39, ix. PubMed ID: 15271396
[TBL] [Abstract][Full Text] [Related]
11. Quantitative approaches to analyzing imatinib-treated chronic myeloid leukemia.
Michor F
Trends Pharmacol Sci; 2007 May; 28(5):197-9. PubMed ID: 17412430
[TBL] [Abstract][Full Text] [Related]
12. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells.
Mishra S; Zhang B; Cunnick JM; Heisterkamp N; Groffen J
Cancer Res; 2006 May; 66(10):5387-93. PubMed ID: 16707466
[TBL] [Abstract][Full Text] [Related]
13. Resistance to targeted therapy in chronic myelogenous leukemia.
Hochhaus A; Erben P; Ernst T; Mueller MC
Semin Hematol; 2007 Jan; 44(1 Suppl 1):S15-24. PubMed ID: 17292737
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant.
Qin YZ; Jiang B; Jiang Q; Zhang Y; Jiang H; Li JL; Zhu HH; Li LD; Liu YR; Chen SS; Huang XJ
Acta Haematol; 2008; 120(3):146-9. PubMed ID: 19039205
[TBL] [Abstract][Full Text] [Related]
15. Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?
Breccia M; Frustaci AM; Cannella L; Soverini S; Stefanizzi C; Federico V; Grammatico S; Santopietro M; Alimena G
Cancer Chemother Pharmacol; 2009 Jun; 64(1):195-7. PubMed ID: 19156415
[TBL] [Abstract][Full Text] [Related]
16. Current and emerging treatment options in chronic myeloid leukemia.
Jabbour E; Cortes JE; Giles FJ; O'Brien S; Kantarjian HM
Cancer; 2007 Jun; 109(11):2171-81. PubMed ID: 17431887
[TBL] [Abstract][Full Text] [Related]
17. Dose escalation of imatinib in chronic-phase chronic myeloid leukemia patients: is it still reasonable?
Rudzki J; Wolf D
Expert Rev Hematol; 2011 Apr; 4(2):153-9. PubMed ID: 21495925
[TBL] [Abstract][Full Text] [Related]
18. Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.
La Rosée P; Jia T; Demehri S; Härtel N; de Vries P; Bonham L; Hollenback D; Singer JW; Melo JV; Druker BJ; Deininger MW
Clin Cancer Res; 2006 Nov; 12(21):6540-6. PubMed ID: 17085669
[TBL] [Abstract][Full Text] [Related]
19. Current status of imatinib as frontline therapy for chronic myeloid leukemia.
Marin D
Semin Hematol; 2010 Oct; 47(4):312-8. PubMed ID: 20875547
[TBL] [Abstract][Full Text] [Related]
20. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]